Search
Tifuvirtide
go.drugbank.com/drugs/DB05413InvestigationalTifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.
CYT-6091
go.drugbank.com/drugs/DB05991ExperimentalIt was under investagtion in clinical trials NCT00356980 and NCT00436410 for the treatment of various cancers. … CYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold
Categories: Compounds used in a research, industrial, or household settingBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigational[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients … Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: MEKTOVI® 15 MG TABLETAS RECUBIERTASSucrose
go.drugbank.com/drugs/DB02772ApprovedInvestigationalIt is obtained commercially from sugarcane, sugar beet (beta vulgaris), and other plants and used extensively as a food and a sweetener. … A nonreducing disaccharide composed of glucose and fructose linked via their anomeric carbons.
Categories: Compounds used in a research, industrial, or household settingSynonyms: 1-alpha-D-Glucopyranosyl-2-beta-D-fructofuranosideAzilsartan mopivabil
go.drugbank.com/drugs/DB21569ExperimentalThe usage of the INN stem '-sartan' in the name indicates that Azilsartan mopivabil is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). … Azilsartan mopivabil has a monoisotopic molecular weight of 676.25 Da.
Dofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation … and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetididePimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalIn fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigational[A238914] On September 20, 2021, the FDA granted accelerated approval to tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer in adults in whom the disease progressed during … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesISF402
go.drugbank.com/drugs/DB06315ExperimentalISF402 is an investigational peptide tetramer which helps dispersal of insulin via zinc chelation, therefore allowing insulin hexamers to break free.
AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalAfter phase II trials it was cancelled due to lack of potency. [L2917] … AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc.